Imunon Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $11,639,411 | $11,287,691 |
| General and administrative | 7,493,035 | 9,742,739 |
| Total operating expenses | 19,132,446 | 21,030,430 |
| Loss from operations | (19,132,446) | (21,030,430) |
| Other income (expense): | ||
| Investment income, net | 512,204 | 1,157,625 |
| Loss on debt extinguishment | - | (329,158) |
| Interest expense | - | (197,080) |
| Other expense | - | (396,319) |
| Total other income (expense), net | 512,204 | 235,068 |
| Loss before income tax benefit | (18,620,242) | (20,795,362) |
| Income tax benefit | - | 1,280,385 |
| Net loss | $(18,620,242) | $(19,514,977) |
| Net loss per common share - basic and diluted | $(1.62) | $(2.16) |
| Weighted average common shares outstanding - basic and diluted | 11,508,159 | 9,045,320 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.